A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation

CompletedOBSERVATIONAL
Enrollment

99

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions
Hepatitis C Virus (HCV)
Trial Locations (8)

115093

Children's Clinical Multidisciplinary Center of the Moscow Region /ID# 226590, Moscow

125310

Infectious Clinical Hosp #1 /ID# 218497, Moscow

367000

Dagestan State Medical University /ID# 218500, Makhachkala

420140

A.F.Agafonov Republican Clinical Infectious Hospital /ID# 218498, Kazan'

443029

Samara Region Clinical HIV/AIDS Prevention and Control Center /ID# 218499, Samara

454048

South-Ural Medical State University /ID# 218501, Chelyabinsk

620102

Sverdlovsk Regional Center of AIDS Prevention and Control /ID# 222253, Yekaterinburg

664035

Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 222252, Irkutsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY